首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1974211篇
  免费   143048篇
  国内免费   3978篇
耳鼻咽喉   28504篇
儿科学   64862篇
妇产科学   57532篇
基础医学   285867篇
口腔科学   55559篇
临床医学   167931篇
内科学   388354篇
皮肤病学   41683篇
神经病学   155021篇
特种医学   77909篇
外国民族医学   672篇
外科学   307575篇
综合类   42224篇
现状与发展   1篇
一般理论   525篇
预防医学   145528篇
眼科学   45660篇
药学   147337篇
  1篇
中国医学   3887篇
肿瘤学   104605篇
  2018年   18906篇
  2016年   16083篇
  2015年   18431篇
  2014年   25965篇
  2013年   39723篇
  2012年   53867篇
  2011年   57711篇
  2010年   34555篇
  2009年   32648篇
  2008年   55563篇
  2007年   59732篇
  2006年   60637篇
  2005年   59414篇
  2004年   57050篇
  2003年   55381篇
  2002年   54516篇
  2001年   88092篇
  2000年   90529篇
  1999年   77333篇
  1998年   21917篇
  1997年   19812篇
  1996年   19936篇
  1995年   18713篇
  1994年   17814篇
  1993年   16642篇
  1992年   61860篇
  1991年   60462篇
  1990年   59459篇
  1989年   57538篇
  1988年   53735篇
  1987年   52700篇
  1986年   50429篇
  1985年   48154篇
  1984年   36067篇
  1983年   31090篇
  1982年   18679篇
  1981年   16427篇
  1979年   34059篇
  1978年   23944篇
  1977年   20521篇
  1976年   19427篇
  1975年   21360篇
  1974年   25266篇
  1973年   24304篇
  1972年   23124篇
  1971年   21516篇
  1970年   20249篇
  1969年   19218篇
  1968年   18229篇
  1967年   16289篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets.  相似文献   
102.
103.
104.

Background

Arterial vascular anomalies in patients undergoing kidney transplantation (KT) are correlated with a higher incidence of early surgical complications, potentially causing graft loss. Arterial reconstruction allows patients to overcome these surgical challenges, thus minimizing the risk of poor outcomes. The aim of the present study is to retrospectively investigate the safety and effectiveness of the multiple arterial reconstruction technique with a Teflon patch in case of an unavailable aortic patch: to do so, surgical complications, graft function, and patient survival were evaluated.

Methods

During the period January 2009 to August 2016, 202 adult deceased-donor KTs were performed at our center. Group A (n = 27; reconstruction of multiple arteries) and Group B (n = 175; control group) were compared.

Results

No differences were observed between the 2 groups in terms of early postoperative course, with no vascular complication observed in Group A. No vascular patch infections were reported, nor longer cold ischemia time rates. Similarly, long-term survival rates were similar between the 2 groups.

Conclusions

The Teflon-patch arterial reconstruction technique appears to be safe and effective, with an acceptable balance of benefits and potential risks of using a prosthetic material. Studies based on larger series are needed to further validate this approach.  相似文献   
105.
106.
107.
108.
109.
BackgroundThe aim of this paper is to assess the current state of quality and outcomes measures being reported for hepatic resections in the recent literature.MethodsMedline and PubMed databases were searched for English language articles published between 1 January 2002 and 30 April 2013. Two examiners reviewed each article and relevant citations for appropriateness of inclusion, which excluded papers of liver donor hepatic resections, repeat hepatectomies or meta-analyses. Data were extracted and summarized by two examiners for analysis.ResultsFifty-five studies were identified with suitable reporting to assess peri-operative mortality in hepatic resections. In only 35% (19/55) of the studies was the follow-up time explicitly stated, and in 47% (26/55) of studies peri-operative mortality was limited to in-hospital or 30 days. The time period in which complications were captured was not explicitly stated in 19 out of 28 studies. The remaining studies only captured complications within 30 days of the index operation (8/28). There was a paucity of quality literature addressing truly patient-centred outcomes.ConclusionQuality outcomes after a hepatic resection are inconsistently reported in the literature. Quality outcome studies for a hepatectomy should report mortality and morbidity at a minimum of 90 days after surgery.  相似文献   
110.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号